Open access · US-GOV
via ClinicalTrials.gov Clinical trial
ctDNA-Guided Mosunetuzumab Consolidation Therapy in Older Patients With Untreated DLBCL
Authors not listed
Danielle Wallace · 2025
Abstract
Older patients with diffuse large B- cell lymphoma (DLBCL) do not have the same rates of disease control as younger patients and are at risk for toxicity. Identifying which patients might benefit from more therapy at the end of first-line treatment is important. The ability to measure small amounts of persistent lymphoma (circulating tumor DNA or ctDNA) might allow the investigators to risk stratify patients. If older patients have detectable ctDNA in the blood at the end of six cycles of polatuzumab vedotin, rituximab and dose-attentuated CHP chemotherapy, patients will receive a bispecific antibody called mosunetuzumab. The investigators hypothesize this will result in "clearing" the ctDNA from the blood and result in better disease control and outcomes for patients. The study will also measure the safety of this regimen and the impact on the function of these older patients utilizing a tool called the geriatric assessment.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-07 MST
Cite this
APA
Anonymous. (2025). ctDNA-Guided Mosunetuzumab Consolidation Therapy in Older Patients With Untreated DLBCL. <em>Danielle Wallace</em>. https://clinicaltrials.gov/study/NCT06828991
Vancouver
Anonymous. ctDNA-Guided Mosunetuzumab Consolidation Therapy in Older Patients With Untreated DLBCL. Danielle Wallace. 2025.
BibTeX
@misc{anon2025ctDNAG,
title = {ctDNA-Guided Mosunetuzumab Consolidation Therapy in Older Patients With Untreated DLBCL},
author = {Anonymous},
journal = {Danielle Wallace},
year = {2025},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Royal College of Surgeons, Ireland 2022
Open access · US-GOV
Impact of Dietary Assessment and Intervention on Outcomes in Liver Cirrhosis Patients
Tufts Medical Center 2021
Open access · US-GOV
Improving Medical Decision Making for Older Patients With End Stage Renal Disease
University Hospital, Strasbourg, France 2012
Open access · US-GOV
Evaluation of fMRI-SAM in the Early Detection of Alzheimer's Disease.
Dana-Farber Cancer Institute 2024
Open access · US-GOV
Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments
Oncology Letters 2016
Open access · OA
Methylation status of the APC and RASSF1A promoter in cell-free circulating DNA and its prognostic role in patients with colorectal cancer
Hoffmann-La Roche 2019
Open access · US-GOV